Published in Cancer Manag Res on July 26, 2013
Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res (2016) 0.88
Small but mighty: microparticles as mediators of tumor progression. Cancer Microenviron (2014) 0.86
Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study. Meta Gene (2015) 0.79
Co-occurrence of multiple cerebral infarctions due to hypercoagulability associated with malignancy and meningeal carcinomatosis as the initial manifestation of gastric cancer. BMC Neurol (2014) 0.77
Combined pulmonary venous thromboembolism and renal artery thrombosis in a patient with non-small cell lung cancer. Clin Kidney J (2014) 0.75
Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study. Medicine (Baltimore) (2016) 0.75
Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis. Sci Rep (2017) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med (2006) 4.10
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) (1999) 2.85
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med (2006) 2.02
Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol (2007) 1.92
Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost (2005) 1.77
High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62
Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation (2012) 1.60
Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke (2012) 1.52
Upper extremity deep venous thrombosis. Semin Thromb Hemost (2002) 1.43
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol (2011) 1.40
Risk factors for venous thromboembolism. J Am Coll Cardiol (2010) 1.38
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Epidemiology of thrombosis in cancer. Acta Haematol (2001) 1.33
Y chromosome STR haplotypes and the genetic structure of U.S. populations of African, European, and Hispanic ancestry. Genome Res (2003) 1.30
Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res (2012) 1.05
Thrombophilic state in cancer, part I: biology, incidence, and risk factors. J Surg Oncol (2011) 1.01
Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol (2001) 1.00
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol (2012) 0.99
Genetic link between cancer and thrombosis. J Clin Oncol (2009) 0.93
Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol (1989) 0.92
Population genetics of venous thromboembolism. A narrative review. Thromb Haemost (2010) 0.91
The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost (2008) 0.86
Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location. Intern Med J (2012) 0.85
Diagnosis and management of deep vein thrombosis of the upper extremity: a review. Eur Radiol (2004) 0.81
Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors. J Clin Lab Anal (2012) 0.78
Genetic factors and breast cancer laterality. Cancer Manag Res (2014) 0.83
Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res (2014) 0.81